{"id":"ss1dsfv-pe38","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"variants":[{"slug":"ss1-dsfv-pe38","route":"","brandName":"ss1-dsfv-pe38","description":"ss1-dsfv-pe38","formulation":""}],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"CHEMBL3712878","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"Mesothelin binding agent","technicalDetail":""},"_scrapedAt":"2026-03-28T05:38:10.442Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"isCanonical":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01362790","phase":"PHASE1, PHASE2","title":"SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-11","conditions":"Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms","enrollment":55},{"nctId":"NCT01445392","phase":"PHASE1","title":"SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-11-14","conditions":"Mesothelioma","enrollment":24},{"nctId":"NCT01051934","phase":"PHASE1","title":"A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-12-29","conditions":"Non-Small Cell Lung Cancer, Adenocarcinoma","enrollment":2},{"nctId":"NCT00066651","phase":"PHASE1","title":"Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-07","conditions":"Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer","enrollment":""},{"nctId":"NCT00006981","phase":"PHASE1","title":"Immunotoxin Therapy in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-12","conditions":"Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer","enrollment":""},{"nctId":"NCT00024674","phase":"PHASE1","title":"Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days","status":"WITHDRAWN","sponsor":"INSYS Therapeutics Inc","startDate":"2001-02","conditions":"Neoplasms","enrollment":""},{"nctId":"NCT00024687","phase":"PHASE1","title":"Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses","status":"WITHDRAWN","sponsor":"INSYS Therapeutics Inc","startDate":"2000-11","conditions":"Neoplasms","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":11,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_1","status":"active","brandName":"SS1(DSFV)-PE38","genericName":"SS1(DSFV)-PE38","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SS1(DSFV)-PE38 is a mesothelin binding agent used in cancer treatment. It has been studied in combination with pemetrexed and cisplatin to treat malignant pleural mesothelioma, as well as other conditions such as non-small cell lung cancer and pancreatic neoplasms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}